Expanding sales of Imperial Brands’ next generation products into new markets has more than compensated the company for the effect of the US Food and Drug Administration (FDA)’s marketing denial order (MDO) for its Myblu vaping product.
The company said new markets for vapour, heated tobacco and modern oral products – which it groups together as its next generation product (NGP) segment – brought in more than enough new revenue to offset the loss of Myblu from the US market.
Get access to premium content that is normally only available for subscribers.
For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the TobaccoIntelligence team.